Cover Image
市場調查報告書

美國的麻醉劑市場預測 2020年:丙泊酚、苯二氮平類、K他命、Methohexital Sodium

U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), Route of Administration (Intravenous, Inhalational), Supply Chain, Competitive Analysis: Forecast to 2020

出版商 MarketsandMarkets 商品編碼 241469
出版日期 內容資訊 英文 127 Pages
訂單完成後即時交付
價格
Back to Top
美國的麻醉劑市場預測 2020年:丙泊酚、苯二氮平類、K他命、Methohexital Sodium U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), Route of Administration (Intravenous, Inhalational), Supply Chain, Competitive Analysis: Forecast to 2020
出版日期: 2015年07月24日 內容資訊: 英文 127 Pages
簡介

美國的麻醉劑市場,在本調查中區分為分子及給藥途徑。依據分子,分為丙泊酚、苯二氮平類、K他命 (S-(+)-K他命 HCL) 及Methohexital Sodium。預計丙泊酚為成長最快速的區分。依據給藥途徑,分為靜脈注射及吸入。靜脈注射預計2015年在美國的全身麻醉劑市場中構成最大的佔有率。

本報告以美國的麻醉劑市場為主題,提供分子及給藥途徑分類的調查分析、美國的全身麻醉劑市場上主要企業的產品系列相關總括資訊、市場策略、地區及產業區分的詳細調查、美國的全身麻醉劑市場進入相關總括資訊等彙整資料。

第1章 簡介

第2章 調查手法

第3章 市場概要

  • 市場分析
  • 市場動態
  • 市場規模

第4章 流通結構

  • 美國的K他命市場:流通結構
  • 美國的K他命市場
    • 各製造廠商
    • 各流通管道
  • 法規藥物主要的法律上的趨勢
    • 美國的麻醉劑製造相關的遵守
    • 美國的麻醉劑供應商相關的遵守
  • 產品分類的一覽表
    • K他命
    • 其他品牌
  • 市場佔有率
    • 各主要產品
    • 各主要企業

第5章 產品分析

  • 美國的麻醉劑市場區分
  • 美國:市場佔有率,全身麻醉劑
    • 領導品牌/分子
  • 美國的競爭
    • 主要的競爭者
    • 價格
    • 領導品牌
  • 內銷價格
    • K他命的生產者價格
  • 美國的潛在購買者
    • 各州

第6章 美國的麻醉劑市場:主要資訊

  • 美國的進出口制度
    • 法規藥物的進口
    • 法規藥物的出口
    • 關稅為基礎
    • 運輸為基礎
    • 報關手續
    • 非關稅壁壘
  • 主要的相關展示會
  • 潛在購買者的說明

第7章 進入美國麻醉劑市場的策略性建議

第8章 企業簡介

  • 簡介
  • ABBOTT LABORATORIES
  • ASTRAZENECA PLC
  • BAXTER INTERNATIONAL INC.
  • HIKMA PHARMACEUTICALS PLC
  • MYLAN N.V.
  • Eisai
  • FRESENIUS SE & CO. KGAA
  • HOSPIRA, INC.
  • PAR PHARMACEUTICAL COMPANIES, INC.

第9章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PH 1174

The report segments the U.S. general anesthesia drugs market on the basis of molecule and route of administration. On the basis of molecules, the market is divided into Propofol, Benzodiazepine, Ketamine (S-(+)-Ketamine HCL), and Methohexital Sodium. Propofol is expected to be fastest-growing segment, owing to its greater preference and rapid onset of action.

On the basis of route of administration, the U.S. general anesthesia drugs market is bifurcated into intravenous and inhalational. The intravenous segment is expected to account for the largest share of the U.S. general anesthesia drugs market in 2015. Greater patient compliance and less number of side effects as compared to inhalational anesthetics are driving the growth of this market.

Acquisitions was the most preferred strategy adopted by major industry players in order to increase their market shares and cater to unmet needs.

This report provides insights on the qualitative data, market size, growth of various segments and subsegments, and prominent players in this market. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and threats). The report also offers market sizes and data on the growth of various segments in the industry. It focuses on emerging and high-growth segments, high-growth regions, and government initiatives. The report also provides a company profiles section, which comprises basic views on the key players in the U.S. general anesthesia drugs market and their product portfolios, developments, and strategies adopted to maintain and increase their market shares. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms, garner a greater market share. Firms purchasing the report can use any one or a combination of the below-mentioned three strategies (market penetration, competitive assessment, and market entry).

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product portfolios of the top players in the U.S. general anesthesia drugs market. The report analyzes the U.S. general anesthesia drugs market by molecule and mode of administration.
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the U.S. general anesthesia drugs market
  • Market Entry: Comprehensive information about business strategies for entering the U.S. general anesthesia drugs market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET BREAKDOWN AND DATA TRIANGULATION
    • 2.2.1. KEY DATA FROM SECONDARY SOURCES
    • 2.2.2. KEY DATA FROM PRIMARY SOURCES
    • 2.2.3. KEY INDUSTRY INSIGHTS
  • 2.3. ASSUMPTIONS FOR THE STUDY

3. MARKET OVERVIEW

  • 3.1. MARKET ANALYSIS
  • 3.2. MARKET DYNAMICS
    • 3.2.1. DRIVERS
      • 3.2.1.1. Rapid rise in ageing population
      • 3.2.1.2. Rising prevalence of cardiovascular and respiratory system-related diseases
      • 3.2.1.3. Rising number of emergency surgeries
    • 3.2.2. RESTAINTS
      • 3.2.2.1. Side effects associated with general anesthetic usage
      • 3.2.2.2. Regulatory issues
    • 3.2.3. OPPORTUNITIES
      • 3.2.3.1. Patent expiry of Lusedra
  • 3.3. MARKET SIZE
    • 3.3.1. HISTORICAL MARKET TRENDS, 2010-2014
    • 3.3.2. MARKET FORECASTS, 2015-2020

4. DISTRIBUTION STRUCTURE

  • 4.1. U.S. KETAMINE MARKET: DISTRIBUTION STRUCTURE
  • 4.2. U.S. KETAMINE MARKET, 2010-2014
    • 4.2.1. U.S. KETAMINE MARKET, BY MANUFACTURER
    • 4.2.2. U.S. KETAMINE MARKET, BY DISTRIBUTION CHANNEL
      • 4.2.2.1. Group Purchasing Organizations (GPOs)
      • 4.2.2.2. Distributors
  • 4.3. MAJOR LEGAL TRENDS FOR CONTROLLED SUBSTANCES
    • 4.3.1. COMPLIANCE ASSOCIATED WITH MANUFACTURING OF NARCOTICS IN THE U.S.
      • 4.3.1.1. Registration
      • 4.3.1.2. Security
      • 4.3.1.3. Labeling and packaging
      • 4.3.1.4. Inventory
      • 4.3.1.5. Records
    • 4.3.2. COMPLIANCE ASSOCIATED WITH VENDORS OF NARCOTICS IN THE U.S.
  • 4.4. PRODUCT CATEGORY ENUMERATION
    • 4.4.1. KETAMINE
    • 4.4.2. OTHER BRANDS
  • 4.5. MARKET SHARE, 2010-2014
    • 4.5.1. MARKET SHARE, BY KEY PRODUCT
    • 4.5.2. MARKET SHARE, BY KEY PLAYER

5. PRODUCT ANALYSIS

  • 5.1. ANESTHESIA DRUGS MARKET SEGMENTATION IN THE U.S.
    • 5.1.1. GENERAL ANESTHESIA DRUGS MARKET SEGMENTATION
  • 5.2. U.S.: MARKET SHARE, GENERAL ANESTHETICS, 2010-2014
    • 5.2.1. MAJOR BRANDS/MOLECULES
      • 5.2.1.1. Propofol
      • 5.2.1.2. Benzodiazepines
      • 5.2.1.3. Methohexital Sodium
  • 5.3. COMPETITION IN THE U.S.
    • 5.3.1. KEY COMPETITORS
    • 5.3.2. PRICE
    • 5.3.3. MAJOR BRANDS
  • 5.4. LOCAL SALES PRICE
    • 5.4.1. MANUFACTURER PRICE OF KETAMINE
  • 5.5. POTENTIAL BUYERS IN THE U.S.
    • 5.5.1. POTENTIAL BUYERS, BY STATE

6. U.S. GENERAL ANESTHESIA DRUGS MARKET: KEY INFORMATION

  • 6.1. IMPORT & EXPORT SYSTEMS IN THE U.S.
    • 6.1.1. IMPORT OF CONTROLLED SUBSTANCES
      • 6.1.1.1. Shipment of controlled substances
      • 6.1.1.2. Applicants for import and export of controlled substances
    • 6.1.2. EXPORT OF CONTROLLED SUBSTANCES
      • 6.1.2.1. Exception for exportation for special scientific purposes
    • 6.1.3. BASED ON TARIFFS
      • 6.1.3.1. Custom tariff for import
    • 6.1.4. BASED ON TRANSPORT
    • 6.1.5. CUSTOMS CLEARANCE
    • 6.1.6. NON-TARIFF BARRIERS
  • 6.2. TOP RELATED EXHIBITIONS
  • 6.3. DESCRIPTION OF POTENTIAL BUYERS

7. STRATEGIC RECOMMENDATIONS FOR ENTERING THE U.S. GENERAL ANESTHESIA DRUGS MARKET

8. COMPANY PROFILES

  • 8.1. INTRODUCTION
  • 8.2. ABBOTT LABORATORIES
  • 8.3. ASTRAZENECA PLC
  • 8.4. BAXTER INTERNATIONAL INC.
  • 8.5. HIKMA PHARMACEUTICALS PLC
  • 8.6. MYLAN N.V.
  • 8.7. EISAI CO., LTD.
  • 8.8. FRESENIUS SE & CO. KGAA
  • 8.9. HOSPIRA, INC.
  • 8.10. PAR PHARMACEUTICAL COMPANIES, INC.

*Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.

9. APPENDIX

  • 9.1. INSIGHTS OF INDUSTRY EXPERTS
  • 9.2. DISCUSSION GUIDE
  • 9.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 9.4. AVAILABLE CUSTOMIZATIONS
  • 9.5. REGULATIONS FOR CONTROLLED SUBSTANCES IN THE U.S.
  • 9.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: AGEING POPULATION AND RISING NUMBER OF EMERGENCY SURGERIES TO DRIVE THE U.S. GENERAL ANESTHESIA DRUGS MARKET
  • TABLE 2: SIDE EFFECTS OF GENERAL ANESTHETICS AND REGULATORY ISSUES TO HINDER MARKET GROWTH
  • TABLE 3: PATENT EXPIRY OF LUSEDRA OFFER SIGNIFICANT GROWTH OPPORTUNITIES FOR THE MARKET PLAYERS
  • TABLE 4: U.S.: KETAMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2010-2014 (USD MILLION)
  • TABLE 5: U.S.: KETAMINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2015-2020 (USD MILLION)
  • TABLE 6: U.S.: KETAMINE MARKET SIZE, BY MANUFACTURER, 2010-2014 (USD MILLION)
  • TABLE 7: U.S.: KETAMINE MARKET SIZE, BY MANUFACTURER, 2010-2014 (KILOGRAM)
  • TABLE 8: U.S.: KETAMINE MARKET SIZE, BY MANUFACTURER, 2015-2020 (USD MILLION)
  • TABLE 9: U.S.: KETAMINE MARKET SIZE, BY MANUFACTURER, 2015-2020 (KILOGRAM)
  • TABLE 10: U.S.: KETAMINE MARKET SIZE, BY GPO, 2010-2014 (USD MILLION)
  • TABLE 11: U.S.: KETAMINE MARKET SIZE, BY GPO, 2010-2014 (KILOGRAM)
  • TABLE 12: U.S. KETAMINE MARKET SIZE, BY GPO, 2015-2020 (USD MILLION)
  • TABLE 13: U.S.: KETAMINE MARKET SIZE, BY GPO, 2015-2020 (KILOGRAM)
  • TABLE 14: U.S.: KETAMINE MARKET SIZE, BY DISTRIBUTOR, 2010-2014 (USD MILLION)
  • TABLE 15: U.S.: KETAMINE MARKET SIZE, BY DISTRIBUTOR, 2010-2014 (KILOGRAM)
  • TABLE 16: U.S.: KETAMINE MARKET SIZE, BY DISTRIBUTOR, 2015-2020 (USD MILLION)
  • TABLE 17: U.S.: KETAMINE MARKET SIZE, BY DISTRIBUTOR, 2015-2020 (KILOGRAM)
  • TABLE 18: ANESTHESIA DRUGS MARKET SIZE, BY TYPE, 2010-2014 (USD MILLION)
  • TABLE 19: ANESTHESIA DRUGS MARKET SIZE, BY TYPE, 2015-2020 (USD MILLION)
  • TABLE 20: U.S. ANESTHESIA DRUGS MARKET SIZE, BY TYPE, 2010-2014 (USD MILLION)
  • TABLE 21: U.S. ANESTHESIA DRUGS MARKET SIZE, BY TYPE, 2015-2020 (USD MILLION)
  • TABLE 22: U.S. GENERAL ANESTHESIA DRUGS MARKET SIZE, BY TYPE, 2010-2014 (USD MILLION)
  • TABLE 23: KETAMINE: MAJOR COMPETITOR BRANDS & MOLECULES
  • TABLE 24: U.S. GENERAL INTRAVENOUS ANESTHESIA DRUGS MARKET SIZE, BY MOLECULE, 2010-2014 (USD MILLION)
  • TABLE 25: U.S. GENERAL INTRAVENOUS ANESTHESIA DRUGS MARKET SIZE, BY MOLECULE, 2015-2020 (USD MILLION)
  • TABLE 26: KETAMINE: PRICE, 2012 (USD)
  • TABLE 27: METHOHEXITAL SODIUM PRICE, 2012 (USD)
  • TABLE 28: FOSPROPOFOL DISODIUM PRICE, 2012 (USD)
  • TABLE 29: PENTOBARBITAL SODIUM PRICE, 2012 (USD)
  • TABLE 30: PROPOFOL PRICE, 2012 (USD)
  • TABLE 31: MIDAZOLAM PRICE, 2012 (USD)
  • TABLE 32: ETOMIDATE SODIUM PRICE, 2012 (USD)
  • TABLE 33: TOTAL PER STUDY COST OF CLINICAL TRIALS, BY PHASE, (USD MILLION)
  • TABLE 34: KETAMINE PRICE, 2012 (USD)
  • TABLE 35: GENERAL INTRAVENOUS ANESTHESIA DRUGS: USAGE TRENDS
  • TABLE 36: U.S.: TOP ABUSED PRESCRIPTION DRUGS, 2013
  • TABLE 37: MANUFACTURER PRICE OF KETAMINE, 2012
  • TABLE 38: GROUP PURCHASING ORGANIZATIONS, BY STATE
  • TABLE 39: DISTRIBUTORS, BY STATE
  • TABLE 40: HARMONIZED TARIFF SCHEDULE FOR ANESTHESIA DRUGS
  • TABLE 41: ANESTHESIA MOLECULES: CHEMICAL ABSTRACTS SERVICES (CAS) NUMBERS
  • TABLE 42: REGULATORY REQUIREMENTS FOR CONTROLLED SUBSTANCES
  • TABLE 43: ANESTHESIA EXHIBITIONS
  • TABLE 44: POTENTIAL GROUP PURCHASING ORGANIZATIONS
  • TABLE 45: POTENTIAL DISTRIBUTORS

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN: U.S. GENERAL ANESTHESIA DRUGS MARKET
  • FIGURE 2: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND COUNTRY/REGION
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: GROWING BASE OF AGEING POPULATION AND RISING PREVALENCE OF CARDIOVASCULAR AND RESPIRATORY DISEASES TO BOOST THE GROWTH OF U.S. GENERAL ANESTHESIA DRUGS MARKET
  • FIGURE 7: U.S. KETAMINE MARKET SIZE, 2010 VS. 2014 (USD MILLION)
  • FIGURE 8: U.S. KETAMINE MARKET SIZE, BY ITEM, 2010 VS. 2014 (USD MILLION)
  • FIGURE 9: U.S. KETAMINE MARKET SIZE, 2010-2014 (USD MILLION)
  • FIGURE 10: U.S. KETAMINE MARKET SIZE, 2015-2020 (USD MILLION)
  • FIGURE 11: DISTRIBUTION STRUCTURE
  • FIGURE 12: U.S. KETAMINE MARKET SHARE, BY GPO (2014)
  • FIGURE 13: U.S. KETAMINE MARKET SHARE, BY DISTRIBUTOR (2014)
  • FIGURE 14: U.S. KETAMINE MARKET SIZE, BY BRAND, 2010-2014 (USD MILLION)
  • FIGURE 15: U.S. KETAMINE MARKET SHARE, BY KEY PRODUCT, 2010 VS. 2014
  • FIGURE 16: U.S. KETAMINE MARKET SHARE, BY KEY PLAYER, 2010 VS. 2014
  • FIGURE 17: ANESTHETICS MARKET SEGMENTATION
  • FIGURE 18: LOCATION QUOTIENT OF ANESTHESIA SPECIALISTS IN THE U.S., BY STATE (MAY 2014)
  • FIGURE 19: ANESTHESIA LANDSCAPE
  • FIGURE 20: GENERAL ANESTHETICS LANDSCAPE
  • FIGURE 21: MARKET SIZE, BY MOLECULE, 2010 & 2020 (USD MILLION)
  • FIGURE 22: PROPERTIES OF INTRAVENOUS ANESTHESIA DRUGS
  • FIGURE 23: GENERAL INTRAVENOUS ANESTHESIA DRUGS MARKET SIZE, BY MOLECULE, 2014 (USD MILLION)
  • FIGURE 24: CUSTOM CLEARANCE PROCEDURE FOR IMPORT OF CONTROLLED SUBSTANCES IN THE U.S.
  • FIGURE 25: EXPORT CUSTOMS CLEARANCE PROCEDURE FOR CONTROLLED SUBSTANCES IN THE U.S.
  • FIGURE 26: BUSINESS STRATEGY
  • FIGURE 27: GEOGRAPHIC REVENUE MIX OF THE TOP THREE MARKET PLAYERS
  • FIGURE 28: ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 29: ASTRAZENECA PLC: COMPANY SNAPSHOT
  • FIGURE 30: BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
  • FIGURE 31: HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT
  • FIGURE 32: MYLAN N.V.: COMPANY SNAPSHOT 80  
  • FIGURE 33: EISAI CO., LTD.: COMPANY SNAPSHOT
  • FIGURE 34: FRESENIUS SE & CO. KGAA: COMPANY SNAPSHOT
  • FIGURE 35: HOSPIRA, INC.: COMPANY SNAPSHOT
  • FIGURE 36: PAR PHARMACEUTICAL COMPANIES, INC.: COMPANY SNAPSHOT
Back to Top